

MT2024-43: A Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Activity of Single Ascending Doses of SBT777101 in Subjects with Rheumatoid Arthritis

Status: Recruiting

Eligibility Criteria

Sex: Male or Female

Age Group: 18 years and over

This study is NOT accepting healthy volunteers

Inclusion Criteria:

- adult-onset, moderate-to-severe rheumatoid arthritis (RA) - Body mass index (BMI) <35 kg/m² - inadequate response to or unable to tolerate available RA therapies - willing to use highly effective methods of contraception - see link to clinicaltrials.gov for complete inclusion criteria

Exclusion Criteria:

- major surgery within 12 weeks prior to screening or planned within 12 months - uncontrolled heart, lung, kidney, liver, endocrine, or gastrointestinal disease - recurrent infections or active infection - see link to clinicaltrials.gov for complete exclusion criteria

Conditions & Interventions

Conditions:

Arthritis & Rheumatic Diseases, Immune Diseases

Keywords:

Autoimmune, Clinics and Surgery Center (CSC), RA, Rheumatoid Arthritis

More Information

Description: The study evaluates the safety and effects of a novel regulatory CARTreg cell-based autoimmune and inflammatory disease therapy for the treatment of rheumatoid arthritis. The therapy is an autologous (using the patient's own cells) Treg cell therapy that targets proteins in the inflamed, disease-associated tissue, with the aim to dampen inflammation and restore balance to the immune system.

Study Contact: Michelle Snyder - snyde003@umn.edu

Principal Investigator: Daniel Mueller

Phase: PHASE1

IRB Number: STUDY00023753

Thank you for choosing StudyFinder. Please visit <http://studyfinder.umn.edu> to find a Study which is right for you and contact sfinder@umn.edu if you have questions or need assistance.